Zentalis Pharmaceuticals, Inc.
ZNTL
$1.61
-$0.02-1.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.03% | -24.11% | 26.99% | 37.37% | 31.73% |
| Total Depreciation and Amortization | -20.66% | -9.31% | -7.20% | -7.23% | -7.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 226.93% | 571.87% | -67.86% | -93.29% | -82.41% |
| Change in Net Operating Assets | -262.82% | 113.22% | -382.06% | 290.97% | 189.93% |
| Cash from Operations | 9.19% | 28.02% | 17.79% | 16.03% | 16.43% |
| Capital Expenditure | 100.00% | 70.95% | 62.09% | 30.88% | 77.33% |
| Sale of Property, Plant, and Equipment | 775.38% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 339.17% | 737.43% | 502.77% | 847.32% | -150.32% |
| Cash from Investing | 338.48% | 721.12% | 497.14% | 815.21% | -151.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -50.35% | -99.88% | -99.85% | -99.88% | -99.80% |
| Repurchase of Common Stock | 100.00% | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -13.54% | -99.88% | -99.95% | -99.96% | -99.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.25% | 206.40% | 138.79% | -201.80% | -208.57% |